Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

NCT03445949 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: short postimplantation dual antiplatelet therapy
DRUG: extended postimplantation dual antiplatelet therapy
DRUG: long-term treatment with a single antiplatelet agent
DRUG: 6 months treatment with a single antiplatelet agent

Sponsor

National Institute of Cardiology, Warsaw, Poland

Collaborators

[object Object]